Proton pump inhibitor use and the antifracture efficacy of alendronate

Archives of Internal Medicine

Volumn 171, Issue 11, 2011, Pages 998-1004

  Abrahamsen, Bo ^a,d   Eiken, Pia ^b   Eastell, Richard ^c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESOMEPRAZOLE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PREDNISOLONE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG USE; FEMALE; FOLLOW UP; FOREARM FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; SPINE FRACTURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CHI-SQUARE DISTRIBUTION; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; REGISTRIES; RISK;

EID: 79959285244     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.20     Document Type: Article

References (32)

1. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747-748.
2. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-781.
3. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162-167.
4. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58(3):288-298.
5. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953.
6. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179 (4):319-326.
7. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989-1998.
8. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmeno-pausal women using omeprazole. Calcif Tissue Int. 2009;84(1):13-19.
9. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170(9):765-771.
10. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959
11. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study (published online June 29,2010). Osteoporos Int. doi:10.1007/s00198-010-1337-8
12. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Cal-cif Tissue Int. 2006;79(2):76-83
13. ATC/DDD Index 2011. http://www.whocc.no/atc_ddd_index/. World Health Organization Collaborating Centre for Drug Statistics Methodology Web site. Accessed February 1, 2010.
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11) 1130-1139.
15. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-1022.
16. Mattsson JP, Väänänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin two proton pump inhibitors: differentiation of theireffects on gastric, kidney and bone H(+)-translocating ATPases. BiochimBiophysActa. 1991;1065(2):261-268.
17. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O'Fallon WM, Melton LJ. Risk of fractures in patients with pernicious anemia. J Bone Miner Res. 1992;7(5) 573-579.
18. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res. 2005;20(6):921-929.
19. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N EnglJ Med. 2004;350(20):2042-2049
20. Perez-Castrillon JL, Arranz-Peña ML, Luis DD. Homocysteine as a predictive factor for hip fracture in older persons. N EnglJ Med. 2004;351(10):1027-1030.
21. Miyao M, Morita H, Hosoi T, et al. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif Tissue Int. 2000;66(3):190-194
22. Villadsen MM, Bünger MH, Carstens M, Stenkjaer L, Langdahl BL. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with osteoporotic vertebral fractures, but is a weak predictor of BMD. Osteoporos Int. 2005;16(4):411-416
23. Abrahamsen B, Jørgensen HL, Nielsen TL, et al. MTHFR c.677C>T polymorphism as an independent predictor of peak bone mass in Danish men: results from the Odense Androgen Study. Bone. 2006;38(2):215-219.
24. Abrahamsen B, Madsen JS, Tofteng CL, et al. Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? analysis of food records from the Danish osteoporosis prevention study. Bone. 2005 36(3):577-583.
25. Figura N, Gennari L, Merlotti D, et al. Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. DigDis Sci. 2005;50(5):847-852.
26. Ensrud KE, Duong T, Cauley JA, et al; Study of Osteoporotic Fractures Research Group. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med. 2000;132(5):345-353.
27. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2510-2519
28. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251-259.
29. Black DM, Cummings SR, Karpf DB, et al; Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541
30. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density butwithoutvertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-2082
31. Saag KG, Emkey R, Schnitzer TJ, et al; Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of gluco-corticoid-induced osteoporosis. NEnglJMed. 1998;339(5):292-299
32. Hundrup YA, Høidrup S, Obel EB, Rasmussen NK. The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register. Scand J Public Health. 2004;32(2):136-143.